Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 expression and PI3K-Akt pathway alterations in gastric cancer.

Digestion - 1 Jan 2014

Sukawa Yasutaka, Yamamoto Hiroyuki, Nosho Katsuhiko, Ito Miki, Igarashi Hisayoshi, Naito Takafumi, Mitsuhashi Kei, Matsunaga Yasutaka, Takahashi Taiga, Mikami Masashi, Adachi Yasushi, Suzuki Hiromu, Shinomura Yasuhisa

Abstract excerpt

The anti-HER2 antibody trastuzumab has led to an era of personalized therapy in gastric cancer (GC). As a result, HER2 expression has become a major concern in GC. HER2 overexpression is seen in 7-34% of GC cases. Trastuzumab is an antibody that targets the HER2 extracellular domain and induces antibody-dependent cellular cytotoxicity and inhibition of the HER2 downstream signals. Mechanisms of resistance to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Phosphatidylinositol 3-Kinase

Share to Proto-Oncogene Proteins c-akt

Share to Receptor, ErbB-2

Share to Stomach Neoplasms

Share to Trastuzumab

Source

Identifiers

PMID: 24458107
DOI: 10.1159/000356201

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 expression and PI3K-Akt pathway alterations in gastric cancer.PMID 24458107Read ↗

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabSemantic proximity Read ↗

HER2/PI3K/AKT pathway in HER2-positive breast cancer: A reviewSemantic proximity Read ↗

PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.Semantic proximity Read ↗

PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.Semantic proximity Read ↗

Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.Semantic proximity Read ↗

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patientsSemantic proximity Read ↗

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive ReviewSemantic proximity Read ↗

Molecular target: pan-AKT in gastric cancerSemantic proximity Read ↗

Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity Read ↗

<i>TNK</i><i>2</i> gene amplification is a novel predictor of a poor prognosis in patients with gastric cancerSemantic proximity Read ↗

The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity Read ↗

Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.